While it was generally assumed that the return to power of business-friendly President Donald Trump would help facilitate M&A activity, his initial marching orders to the Federal Trade Commission suggest otherwise. Trump has instructed the antitrust regulator to continue to scrutinize deals, as it did under the direction of former President Joe Biden. Despite this, there have been indications that the M&A environment is opening up. One Trump measure that could have the unintended consequence of triggering M&A deals is his reductions in funding to the FDA and the National Institutes of Health.
Read the full article: Government Cuts Could Help Spark Surge in Biotech M&A Activity //
Source: https://www.fiercepharma.com/pharma/government-cuts-could-help-spark-surge-ma-activity